Half-year balance sheet

Daniel Schilling,

Strong figures at Kuka

Peter Mohnen was able to present very good half-year figures. © Kuka

Despite difficult conditions, the automation specialist can present a very good result. However, supply chain problems are making it more difficult to process orders.

Kuka AG generated a strong result in the first six months of 2022. At 2,545.4 million euros, the Group's incoming orders between January and June were 34.8% higher than the previous year's figure and sales revenue increased by 13.5% to around 1.7 billion euros. In addition, Kuka increased earnings before interest and taxes (EBIT) to 48.6 million euros (first half of 20 21: 33.8 million euros). The EBIT margin rose to 2.8% in the first half of 20 22.

Record order intake

"In the first half of 2022, we are presenting the highest half-year order intake we have ever had. After just six months, it is more than 2.5 billion euros and thus only just below the figure for the full year 2020," said Peter Mohnen, CEO of Kuka AG. All business units contributed to this strong result. For example, Kuka almost doubled its order intake in China in the first half of 2022.

Despite the high demand, Kuka is also burdened by the difficult economic conditions such as the shortage of semiconductors and the effects of Russia's war of aggression in Ukraine with material bottlenecks, faltering supply chains and rising costs.

Overcoming global uncertainties

"The main challenge at the moment is to generate sales and therefore profits from the orders. Our teams are working hard to ensure that we can manufacture and deliver under considerably more difficult conditions. The global uncertainties and risks will keep us busy for some time to come. But Kuka has the right strategy with new products and solutions for rapidly growing markets," says Peter Mohnen. "The economy is facing enormous global challenges. Automation solutions help companies around the world to tackle these problems."

Advertisement
  • Xing Icon
  • LinkedIn Icon
Advertisement
Advertisement

You might also be interested in

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe to our newsletter
Advertisement
Back to home